AXIM Biotechnologies, Inc.
AXIM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 78.3% | 345.3% | -85.3% | – |
| Gross Profit | -$0 | $0 | -$0 | $0 |
| % Margin | -524.1% | 100% | -4,701.4% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,468.6% | -16,265.7% | -44,398.9% | -21,775.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -4,985.2% | -20,395% | -67,120.7% | -27,320.8% |
| EPS Diluted | -0.011 | -0.035 | -0.036 | -0.13 |
| % Growth | 68.9% | 1.7% | 72.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |